id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-1848-0013,FDA,FDA-2020-D-1848,Clinical Drug Interaction Studies With Combined Oral Contraceptives; Guidance for Industry; Availability,Notice,Notice of Availability,2023-06-09T04:00:00Z,2023,6,2023-06-09T04:00:00Z,,2023-06-09T12:57:33Z,2023-12370,0,0,0900006485aeb35e
FDA-2020-D-1848-0014,FDA,FDA-2020-D-1848,Clinical Drug Interaction Studies With Combined Oral Contraceptives; Guidance for Industry - Final Guidance,Other,Guidance,2023-06-09T04:00:00Z,2023,6,2023-06-09T04:00:00Z,,2025-11-09T10:00:16Z,,1,0,0900006485aeaf8d
FDA-2020-D-1848-0001,FDA,FDA-2020-D-1848,"Clinical Drug Interaction Studies With Combined Oral Contraceptives; Draft
Guidance for Industry; Availability",Notice,Notice of Availability,2020-11-23T05:00:00Z,2020,11,2020-11-23T05:00:00Z,2021-02-23T04:59:59Z,2021-02-23T02:00:36Z,2020-25744,0,0,090000648497009b
FDA-2020-D-1848-0002,FDA,FDA-2020-D-1848,"Clinical Drug Interaction Studies With Combined Oral Contraceptives; Draft
Guidance for Industry; Availability",Other,Guidance,2020-11-23T05:00:00Z,2020,11,2020-11-23T05:00:00Z,,2023-06-09T13:03:55Z,,0,0,0900006484970ac2